CLL1

Creative Biolabs offers a wide range of CLL1 CAR-related products to assist in CART development. Here is a brief list of some CLL1 CAR products. You can also search for the products you are interested in by searching for the corresponding keywords.

Background

CLL-1, known as CD371, is a type II transmembrane glycoprotein with receptor inhibitory function. CLL-1 protein is restricted expressed in myeloid cells as well as in most AML cells. More importantly, CLL-1 is selectively expressed in leukemia stem cells (LSCs) in AML, but not in normal HSCs, making it an excellent therapeutic target for AML.

Associated Diseases

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia

Anti-CLL1 CAR-T Services

CLL1 CAR Design & Construction

Designing the appropriate CAR format is a critical step in CART development. Creative Biolabs has successfully launched a user-friendly online CAR design tool to synthesize customer-preferred CAR formats, including many classical CAR constructions, and special armored CAR constructions.

Fig.1 Schematic diagram of the CLL1 CAR construction.¹

Anti-CLL1 CAR-T In Vitro Assays

Phenotype Analysis of Anti-CLL1 CAR-T

In order to better detect the performance of CART cells when interacting with tumor cells, we have developed a variety of phenotypic detection services via various approaches, including but not limited to proliferation test, activation test, and exhaustion detection.

Fig.2 Representative phenotype of CLL-CART cells by flow cytometry.¹

Anti-CLL1 CAR-T Cytokine Release Test

Multiple cytokine detection provides a convenient detection method for CART studies, which can detect various kinds of cytokines simultaneously when the volume of cell culture supernatant is limited. In addition to multiplex cytokine testing, we also offer other testing methods to meet the different needs of global customers, such as intracellular cytokine flow detection.

Fig.3 Cytokine detection of CLL-1 CAR-T co-cultured with various target cells by multiple cytokine profiling.¹

Anti-CLL1 CAR-T In Vitro Cytotoxicity Assay

In vitro tumor killing assay is a crucial test to verify the target specificity and effectiveness of CART cells against target cells, which provides relevant reference for subsequent in vivo experiments. Creative Biolabs offers a variety of testing services for toxicity verification, such as CSFE- staining test, real-time dynamic cytotoxicity test, etc.

Fig.4 In vitro cytotoxicity test of anti-CLL1 CAR-T cells against different tumor cells.¹

Anti-CLL1 CAR-T In Vivo Assays

In Vivo Animal Models for CLL1 CAR-T

With years of experience in the CART field, Creative Biolabs offers one-stop services for CLL1 CART development. For CART in vivo verification, we offer a wide range of suitable animal models and customized in vivo experimental designs for specific target research.

Fig.5 Schematic diagram of the in vivo experimental design of anti-CLL1 CAR-T.¹

Efficacy Test of Anti-CLL1 CAR-T

Our efficacy testing services focus on evaluating the effectiveness and persistence of CAR-T treatment in killing tumor cells and inhibiting tumor growth in animal models. We test the cytotoxicity of CAR T cells against target tumor cells by various kinds of in vivo assays.

Fig.6 Efficacy assessment of CLL-1 CAR-T cells in U937 xenograft model detected by bioluminescent imaging.¹

Toxicity Evaluation of CLL1 CAR-T

CAR-T toxicity evaluation is designed to assess the safety and potential toxicities associated with the use of CAR-T cells. Creative Biolabs offers a series of CAR-T toxicity testing services, such as off-target study, and phenotype analysis of animal model tissues.

Reference

1. Wang, Jinghua, et al. "CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia." Journal of hematology & oncology 11 (2018): 1-13.